Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Publication year range
2.
Am J Clin Nutr ; 67(2): 317-21, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9459381

ABSTRACT

Psyllium has been reported to inhibit lactulose-induced colonic mass movements and to benefit patients with irritable bowel syndrome, improving both constipation and diarrhea. Our aim was to define how psyllium modified the whole-gut transit of a radiolabeled lactulose-containing test meal by using gamma scintigraphy. Eight subjects participated in a randomized crossover study comparing gastric emptying and small bowel and colonic transit after consumption of 20 mL lactulose three times daily with or without 3.5 g psyllium three times daily. Psyllium significantly delayed gastric emptying: the time to 50% emptying increased from a control value of 69 +/- 9 to 87 +/- 11 min (mean +/- SEM; P < 0.05, n = 8). Small bowel transit was unaltered. However, progression through the colon was delayed with an increase in the percentage of the dose at 24 h in the ascending (control group: 2 +/- 3%, psyllium group: 11 +/- 8%; P < 0.02) and transverse colon (control group: 5 +/- 12%, psyllium group: 21 +/- 14%) with correspondingly less in the descending colon. Although the time for 50% of the isotope to reach the colon was not significantly different with psyllium, psyllium significantly delayed the rise in breath-hydrogen concentrations, which reached 50% of their peak at 217 +/- 34 min compared with control values of 155 +/- 27 min (P < 0.05). Psyllium delays gastric emptying, probably by increasing meal viscosity, and reduces the acceleration of colon transit, possibly by delaying the production of gaseous fermentation products.


Subject(s)
Diarrhea/prevention & control , Gastrointestinal Agents/adverse effects , Gastrointestinal Agents/antagonists & inhibitors , Lactulose/adverse effects , Lactulose/antagonists & inhibitors , Psyllium/therapeutic use , Adult , Colon/drug effects , Cross-Over Studies , Diarrhea/chemically induced , Female , Fermentation/drug effects , Gastric Emptying/drug effects , Gastrointestinal Transit/drug effects , Humans , Hydrogen-Ion Concentration , Male
3.
Can J Physiol Pharmacol ; 76(12): 1103-9, 1998 Dec.
Article in English | MEDLINE | ID: mdl-10326832

ABSTRACT

The effects of [Leu13]motilin were examined in vivo after its intravenous administration into anesthetized dogs and in vitro with isolated preparations of canine mesenteric artery. [Leu13]Motilin (0.1-10 nmol x kg(-1), i.v.) induced both strong and clustered phasic contractions in the gastric antrum and duodenum. At doses of over 1 nmol x kg(-1), [Leu13]motilin also produced transient decreases in arterial blood pressure, left ventricular pressure, maximum rate of rise of left ventricular pressure, and total peripheral resistance, and an increase in aortic blood flow and heart rate. A selective motilin antagonist, GM-109 (Phe-cyclo[Lys-Tyr(3-tBu)-betaAla] trifluoroacetate), completely abolished the gastric antrum and duodenal motor responses induced by [Leu13]motilin. In contrast, hypotension induced by [Leu13]motilin (1 nmol x kg(-1)) was unchanged in the presence of GM-109. In isolated mesenteric artery preparations precontracted with U-46619 (10(-7) M), [Leu13]motilin (10(-8)-10(-5) M) induced an endothelium-dependent relaxation, and this was inhibited by a pretreatment with N(omega)-nitro-L-arginine, a competitive inhibitor of NO synthase (10(-4) M). A high dose (10(-4) M) of GM-109 slightly decreased [Leu13]motilin-induced relaxation, and shifted the concentration-response curve of [Leu13]motilin to the right. However, the pA2 value (4.09) of GM-109 for [Leu13]motilin in the present study was conspicuously lower than that previously demonstrated in the rabbit duodenum (7.37). These results suggest that [Leu13]motilin induces hypotension via the endothelial NO-dependent relaxation mechanism and not through the receptor type that causes upper gastrointestinal contractions.


Subject(s)
Gastrointestinal Agents/pharmacology , Gastrointestinal Motility/drug effects , Hemodynamics/drug effects , Motilin/pharmacology , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Animals , Dogs , Gastrointestinal Agents/antagonists & inhibitors , Hormone Antagonists/pharmacology , Hypotension/chemically induced , Male , Mesenteric Arteries/drug effects , Motilin/antagonists & inhibitors , Peptides, Cyclic/pharmacology , Receptors, Gastrointestinal Hormone/drug effects , Receptors, Neuropeptide/drug effects , Vasoconstrictor Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL